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A B S T R A C T
Purpose
The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally
advanced nasopharyngeal carcinoma is controversial. The individual patient data from theMeta-Analysis
of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments.
Methods
All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopha-
ryngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments
were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-
AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed
by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed-
and random-effects frequentist network meta-analysis models were applied.
Results
The three treatmentswith thehighest probability of beneﬁt onoverall survival (OS)wereCRT-AC, followed
byCRTand IC-CRT,with respective hazard ratios (HRs [95%CIs]) comparedwithRT alone of 0.65 (0.56 to
0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS,
progression-free survival (PFS), locoregional control, and distant control (DC)were, respectively, 0.85 (0.68
to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and
the best for DC. CRT never ranked ﬁrst. HRs of CRT compared with IC-CRT for OS, PFS, locoregional
control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55
(0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity.
Conclusion
The addition of AC to CRT achieved the highest survival beneﬁt and consistent improvement for all
end points. The addition of IC to CRT achieved the highest effect on DC.
J Clin Oncol 35:498-505. © 2016 by American Society of Clinical Oncology
INTRODUCTION
During the past decades, advances in the treatment
of locally advanced nasopharyngeal carcinoma
(NPC) have led to higher cure rates. The individual
patient data (IPD)Meta-Analysis of Chemotherapy
(MAC) in NPC (MAC-NPC) has clearly demon-
strated that the addition of concomitant chemo-
therapy (CT) to radiotherapy (RT) improves
overall survival (OS), progression-free survival
(PFS), locoregional control, and distant control.1
Controversy remains regarding the additional
beneﬁt of induction CT (IC) or adjuvant CT (AC)
to concomitant chemoradiotherapy (CRT). Treat-
ment guidelines, therefore, allow multiple
treatment options.2,3 In the MAC-NPC analysis,
locoregional and distant failure rates at 5 years were
both in the range of 20% in patients receiving CT.1
Although the use of concomitant CTand intensity-
modulated RT (IMRT) has reduced the occurrence
of locoregional relapses,4 distant recurrences
remain a major concern. This underlines the
potential role for additional systemic therapy.
The MAC-NPC meta-analysis mostly eval-
uated the addition of CT to RT compared with RT
alone, but did not formally perform direct
comparisons between the different timings of CT.
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Network meta-analysis (NMA) is a way to determine whether
additional CT is beneﬁcial in the management of NPC. NMA has
been applied to head and neck squamous cell carcinomas5 and was
able to predict the results of randomized trials published after-
ward.6 NMA was planned in the MAC-NPC protocol, and the
presentation of its results is the purpose of this article.
METHODS
MAC-NPC Database and End Point Definitions
The MAC-NPC is an IPD meta-analysis that comprises most ran-
domized trials conducted up to December 31, 2010, evaluating the beneﬁt
of adding CT to local treatment in patients with nonmetastatic NPC. The
inclusion criteria, trial search, trial ﬂowchart, data collection, and checking
have been detailed in a previous publication along with the results of the
standard meta-analysis.1 The primary end point was OS, deﬁned as the
time from randomization until death from any cause. The secondary end
points were PFS and locoregional and distant control. PFS was deﬁned as
the time from randomization to ﬁrst progression (locoregional or distant)
or death. Locoregional and distant control were deﬁned as the time from
randomization to the occurrence of a locoregional or distant failure, re-
spectively. If both a locoregional failure and a distant failure occurred at the
same time, patients were considered as having a distant failure only.
Patients without locoregional and distant failure were censored at the date
of death or last follow-up for those alive. Only severe acute toxicity was
studied. End points included in the network toxicity analysis were those
with a sufﬁcient number of patients, with a signiﬁcant interaction with CT
timing in the standard meta-analysis, and that were considered clinically
relevant. Nausea-vomiting and hematologic toxicities other than neu-
tropenia were not included. The toxicities retained for analysis were
therefore acute neutropenia, mucositis, weight loss, and hearing loss.
Statistical Methods
The NMA was planned in the protocol of the MAC-NPC update. A
detailed statistical analysis plan was written before NMA analysis. A two-
step method was used, the ﬁrst step being the computation of hazard ratios
(HRs) on the basis of the IPD gathered by the MAC-NPC Collaborative
Group, using the Peto estimator for OS and PFS,7 and a competing risk
model for locoregional and distant control.8 The proportional hazards
assumption was checked at each meta-analysis level for OS and PFS.9 The
second step was the actual NMA, using as input data for each trial the two
treatments compared, the logarithm of the HRs, which is usually normally
distributed,5,10,11 and its variance. Therefore, all the analyses were stratiﬁed
by trial. The ﬁrst analysis was initially reported12 using Bayesian model-
ing.13 Because of easier computation and programming, especially for the
handling of multiarm trials or inconsistency, the ﬁnal analysis was per-
formed using a frequentist approach and the R package netmeta,14,15 but
both methods gave similar results and provided the same ranking.
Heterogeneity was quantiﬁed using the I2, which represents the
proportion of total variation in study estimates that is due to heteroge-
neity.16 To limit the number of tests for both heterogeneity and in-
consistency, Ru¨cker14 has proposed a global test, called Q test. This test is
a generalization of Cochran’s test that is used to assess heterogeneity in
conventional meta-analysis. The Q statistic is the sum of a statistic for
heterogeneity and a statistic for inconsistency, which represents the var-
iability of treatment effect between direct and indirect comparisons at the
meta-analytic level. The protocol for the NMA stated that a ﬁxed-effects
model had to be used ﬁrst and that in case of signiﬁcant heterogeneity
(P , .1), two solutions would be investigated: the use of random-effects
models and the performance of sensitivity analyses after the exclusion of
trials that were considered as outliers in the standard meta-analysis.1 The
netmeta package allows identifying in which closed loop the inconsistency
is located.15 The trials responsible for inconsistency could be determined
by comparing direct and indirect estimates and trial forest plots within the
inconsistent closed loop; the effect of trial removal on the network
consistency and estimation could therefore be investigated.
Within the Bayesian framework, the treatments are ranked using the
surface under the cumulative ranking curve.17,18 Ru¨cker and Schwarzer19
have proposed a frequentist analog to surface under the cumulative ranking
curve, which is named P-score, that works without resampling andmeasures
the mean extent of certainty that a treatment is better than the competing
treatments. P-score would be 100%when a treatment is certain to be the best
and 0% when a treatment is certain to be the worst.19 Five-year absolute
beneﬁt was computed using the survival rate at 5 years for the RT-only arms
in MAC-NPC1 and the HR using the method by Stewart and Parmar.20 One
unplanned sensitivity analysis was performed using HR adjusted on patient
sex, age, performance status, and stage. This work was performed in ac-
cordance with published guidelines.21 P values , .05 were considered
signiﬁcant for the difference between treatments. All analyses were per-
formed using the R software (version 3.0.2; R Foundation, Vienna, Austria).
RESULTS
Description of the Network and Patients
The network consists of 20 trials and 5,144 patients: 19 tri-
als22-39 (including one unpublished trial, VUMCA-95), which were
included in the standard meta-analysis (4,806 patients, described
in Blanchard et al1), and one trial (338 patients), which compared
two timings of CT,40 that was ineligible for the standard meta-
analysis. Because of a factorial design in two trials, these 20 trials
were split into 26 comparisons. There were seven different
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Fig 1. Graphical representation of the trial network for overall and progression-
free survival. The size of the nodes is proportional to the number of patients (pts),
which is given in parenthesis in each treatment category. The width of the lines is
proportional to the number of comparisons. The number of trials (t) and pts in each
comparison are displayed next to each line. The network included 26 comparisons
from 20 trials. Six comparisons were counted for the QMH-95 trial (2 3 2 design)
and two for the NPC-9902 trial (2 3 2 design; second randomization on radio-
therapy [RT] modalities). Because of the duplication of QMH-95 trial arms, some
pts are counted multiple times in this ﬁgure (in the RT, concomitant chemo-
radiotherapy [CRT], CRT-adjuvant chemotherapy [AC], and RT-AC groups). How-
ever, the statistical analysis takes into account the correlation structure in this
design and does not give an excessive weight to duplicated patients. IC, induction
chemotherapy.
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treatments: RT alone, which was used as the reference category; IC
followed by RT (IC-RT); RT followed by AC (RT-AC); IC followed
by RT followed by AC (IC-RT-AC); CRT; IC followed by CRT (IC-
CRT); and CRT followed by AC (CRT-AC). Only IC-CRTwas not
directly compared with RT. The network is represented in Figure 1.
The network comprised ﬁve independent closed loops for con-
sistency analysis and one 2 3 2 factorial design trial.27
Median follow-up (interquartile range) was 7.4 years (6.2 to
11.9). Patients (Data Supplement) were mostly male (3,826 patients;
74%), , 50 years of age (3,177 patients; 62%), and had good
performance status (0 in 2,743 patients [65%] and 1 in 1,404 patients
[33%]). Patients presented most frequently with locally advanced
tumor (stage III in 2,519 patients [49%]; stage IVA-B in 2,133 [42%];
and nonkeratinizing histology [WHO grade I in 196 patients; 4%).
Overall Survival
The three treatments that had the highest effect on OS were
CRT-AC, CRT, and IC-CRT, with respective P-scores (higher score
meaning a higher probability of being the best treatment) of 96%,
70%, and 63%, respectively, and corresponding absolute beneﬁt at
5 years of 12%, 8% and 6% compared with radiotherapy alone
(Tables 1 and 2; Data Supplement). There was no signiﬁcant
heterogeneity (I2 = 5.5%; P = .30) or inconsistency (P = .53), and
the proportional hazards assumption was valid. The HRs (95%
CIs) on the basis of the NMA for each pairwise comparison are
presented in the lower left triangle of the league table and in-
structions for reading are given in the footnote of Table 2 (Data
Supplement). Compared with RTalone, the HRs (95% CIs) for OS
for CRT-AC, CRT, and IC-CRT, respectively, were 0.65 (0.56 to
0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). The HRs (95%
CIs) of CRT-AC compared with CRT or IC-CRT showed no sig-
niﬁcant differences, with respective values of 0.85 (0.68 to 1.05)
and 0.81 (0.61 to 1.07).
Secondary End Points
The results of PFS (Tables 1 and 2; Data Supplement) are in
agreement with OS. No heterogeneity (I2 = 0%; P = .25) or in-
consistency (P = .96) was detected for this end point. The three best
treatments were the same as for OS, with CRT-AC being the most
effective, with a P-score of 94%; IC-CRT and CRT, with respective
P-scores of 79% and 52%, ranked second and third. The HRs (95%
CIs) of CRT-AC compared with CRT or IC-CRT were, respectively,
Table 1. Summary of Network Meta-Analysis Results for the Six Treatments Compared With RT Alone and the Four Efﬁcacy End Points
Treatment Data Overall Survival Progression-Free Survival Locoregional Control Distant Control
20 trials,* 5,144 patients 26 comparisons,†
2,070 events
26 comparisons,†
2,489 events
26 comparisons,†
915 events
24 comparisons
1,129 events
P value heterogeneity/inconsistency .39 .58 .68 0.07
P value heterogeneity (within design) .30 .25 .50 0.07
P value inconsistency (between design) .53 .96 .75 0.29
RT
P-score, % 15 4 9 16
IC-RT
HR (95% CI) 0.92 (0.75 to 1.12) 0.78 (0.66 to 0.93) 0.90 (0.70 to 1.15) 0.54 (0.37 to 0.79)
P-score, % 33 46 27 76
5y-AB, % 3 8 2 12
IC-CRT
HR (95% CI) 0.81 (0.63 to 1.04) 0.68 (0.54 to 0.85) 0.80 (0.57 to 1.13) 0.44 (0.27 to 0.71)
P-score, % 63 79 47 95
5y-AB, % 6 13 4 15
CRT
HR (95% CI) 0.77 (0.64 to 0.92) 0.77 (0.65 to 0.91) 0.85 (0.62 to 1.16) 0.68 (0.49 to 0.94)
P-score, % 70 52 37 48
5y-AB, % 8 10 3 8
CRT-AC
HR (95% CI) 0.65 (0.56 to 0.75) 0.62 (0.54 to 0.71) 0.59 (0.46 to 0.76) 0.59 (0.46 to 0.77)
P-score, % 96 94 82 72
5y-AB, % 12 15 7 11
RT-AC
HR (95% CI) 0.96 (0.71 to 1.29) 0.84 (0.63 to 1.11) 0.71 (0.44 to 1.17) 0.91 (0.54 to 1.54)
P-score, % 28 36 58 32
5y-AB, % 1 7 5 2
IC-RT-AC
HR (95% CI) 0.87 (0.58 to 1.30) 0.83 (0.59 to 1.17) 0.50 (0.29 to 0.88) 1.13 (0.62 to 2.05)
P-score, % 45 39 90 10
5y-AB, % 4 6 9 23
NOTE. HRswere estimated using the Peto estimator for overall survival and progression-free survival; subdistribution HRs based on competing risk analyses were used
for locoregional control and distant control. Fixed-effects models were used for overall survival, progression-free survival, and locoregional control and a random-effects
model for distant control. Individual trial (comparison) HRs are given in the Data Supplement.
Abbreviations: 5y-AB, absolute beneﬁt at 5 years compared with RT alone; AC, adjuvant chemotherapy; CRT, concomitant chemoradiotherapy; HR, hazard ratio;
IC, induction chemotherapy; RT, radiotherapy.
*Nineteen trials were previously described in the article by Blanchard et al,1 and the last one was published by Xu et al.40
†One 23 2 factorial design trial27 was analyzed as a multiarm trial and split into six comparisons for proper modeling in the netmeta package and as four independent
trials for the distant control analysis because of computational constraint; the trial NPC-990225 was divided in two independent comparisons
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0.81 (0.66 to 0.98) and 0.92 (0.71 to 1.18). A graphical assessment of
local heterogeneity and inconsistency for OS and PFS is presented in
Figure 2. For PFS, the proportional hazards assumption was not valid
for the comparison of RT to CRT-AC because of the absence of
proportional hazards in the INT-0099 trial. Results of a planned
sensitivity performed after the exclusion of this trial showed the ro-
bustness of the results and the validity of the proportional hazards
assumption (Data Supplement).
The three best treatments for locoregional control were IC-
RT-AC, CRT-AC, and RT-AC, with respective P-scores of 90%,
82%, and 58% (Tables 1 and 2; Data Supplement). There was no
heterogeneity (I2 = 0%, P = .50) or inconsistency (P = 0.75) for this
end point. The comparison between CRT-AC and CRT showed
a nonsigniﬁcant difference in favor of CRT-AC, with an HR (95%
CI) of 0.70 (0.48 to 1.02). Regarding distant control (Tables 1 and
2; Data Supplement), the results are presented using a random
effects NMA because of the presence of heterogeneity (P = .07). No
inconsistency was noticed (P = .29). The three best treatments for
distant control were IC-CRT, IC-RT, and CRT-AC, with respective
P-scores of 95%, 76%, and 72%. The comparison between CRT-
AC and CRT showed the absence of signiﬁcant difference, with an
HR (95% CI) of 0.87 (0.61 to 1.25). CRT was nonsigniﬁcantly
inferior to IC-CRT, with an HR (95% CI) of 1.55 (0.94 to 2.56).
Sensitivity Analyses
Two sensitivity analyses for OS were planned after the ex-
clusion of the two outliers in the standard meta-analysis (INT-
0099,26 Guangzhou 200329) and after excluding the trials that did
not include cisplatin as part of the randomized CT. In these two
analyses, CRT-AC remained ranked ﬁrst and IC-CRT was ranked
second, although closely followed by CRT (Data Supplement). The
unplanned sensitivity analysis on the basis of HR adjusted on
covariates instead of unadjusted HR for OS and PFS did not
signiﬁcantly modify the network estimates, the two ﬁrst treatments
being the same in both cases (Data Supplement).
Results for distant control were not entirely robust to sen-
sitivity analyses. The exclusion of the two trials responsible for
heterogeneity in the standard meta-analysis for distant control
(Int-009926 and QMH-9527) reduced heterogeneity (P = .24) and
improved consistency (P = .41) but changed notably the estimates
and ranking. IC-CRT remained ranked ﬁrst (P-score, 88%; Data
Supplement), but the three next best treatments were RT-AC, IC-
RT, and CRT-AC. When only trials using cisplatin were included
(Data Supplement), IC-CRTand CRT-AC were respectively ranked
ﬁrst and second, with P-scores of 99% and 74%. From a statistical
standpoint, the analyses of locoregional control and distant control
using the Peto estimator led to results similar to the analysis using
competing risk (Data Supplement).
Toxicity
Toxicity analyses were based on slightly different networks
(Data Supplement), and their results are presented in Table 3. CRT-
AC and RT-AC were the most toxic regimens, as measured by their
P-scores, for mucositis/hearing loss and neutropenia/weight loss,
respectively, which underlines the potential toxicity of AC, either
alone or administered with CRT.
DISCUSSION
The major ﬁndings of this IPD NMA of CT in NPC can be
summarized as follows. First, schedules containing concomitant
CTmost often ranked better than schedules without concomitant CT.
Second, when focusing on schedules containing concomitant CT, the
ones with the addition of AC always ranked better than concomitant
CT alone, although the differences in head-to-head comparison were
only signiﬁcant for PFS and locoregional control, whereas IC added to
CRTranked better than CRT for PFS, locoregional control, and distant
control. These results were overall consistent between end points and
robust to sensitivity analyses. Finally, although toxicity data were
available for only aminority of acute toxicities and a subset of trials, the
schedules containing more than one timing of CT generally resulted in
more toxicity than the use of only one timing.
Four NMAs on the role of CT in NPC on the basis of
published data have been reported41-44 in the past year, one as
a full network of all treatments43 and the other three as small
Table 2. Summary Results for Concurrent CRT, With or Without IC or AC
Treatment Compared Overall Survival Progression-Free Survival Locoregional Control Distant Control
CRT-AC v CRT
HR (95% CI) 0.85 (0.68 to 1.05) 0.81 (0.66 to 0.98) 0.70 (0.48 to 1.02) 0.87 (0.61 to 1.25)
5y-AB, % 3.3 5.3 3.3 2.3
CRT-AC v IC-CRT
HR (95% CI) 0.81 (0.61 to 1.07) 0.92 (0.71 to 1.18) 0.74 (0.49 to 1.12) 1.35 (0.80 to 2.31)
5y-AB, % 5.8 2.7 4.7 25.6
CRT v IC-CRT
HR (95% CI) 0.95 (0.72 to 1.25) 1.13 (0.88 to 1.46) 1.05 (0.70 to 1.59) 1.55 (0.94 to 2.56)
5y-AB, % 1.5 24.2 0.9 28.7
NOTE. HRs were estimated using the Peto estimator for OS and PFS; subdistribution HRs based on competing risk analyses were used for locoregional control and
distant control. Fixed-effectsmodels were used for OS, PFS, and locoregional control and a random-effectsmodel for distant control. Individual trial (comparison) HRs are
given in the Data Supplement.
Abbreviations: 5y-AB, absolute beneﬁt at 5 years compared with radiotherapy alone; AC, adjuvant chemotherapy; CRT, concomitant chemoradiotherapy; HR, hazard
ratio; IC, induction chemotherapy.
*Nineteen trials were previously described in the article by Blanchard et al,1 and the last one was published by Xu et al.40
†One 2 3 2 factorial design trial27 was analyzed as a multiarm trial and split into six comparisons for proper modeling in the netmeta package and as four independent
trials for the distant control analysis because of computational constraint; the trial NPC-990225 was divided into two independent comparisons.
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AOCOA
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Meta-analysis fixed
Random
Network meta-analysis
CRT v RT
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Guangzhou 2001
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Network meta-analysis
CRT-AC v RT
INT-0099
QMH-95Comp5
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NPC-9902CF
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Guangzhou 2002-01
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Network meta-analysis
RT-AC v RT
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IC-CRT v IC-RT
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CRT v IC-CRT
NPC008
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Network meta-analysis
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1.00
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0.34
0.71
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0.50
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0.65
0.65
0.95
1.07
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0.96
0.89
0.94
0.91
0.91
0.88
1.56
1.00
1.15
1.15
0.95
0.66
0.79
0.73
0.73
0.85
Overall Survival
HR 95% CI
 0.68 to 1.44
0.75 to 1.33
0.40 to 1.46
0.78 to 1.20
0.78 to 1.20
I² = 0%, P = .78
0.75 to 1.12
0.61 to 1.07
0.57 to 1.75
0.31 to 0.93
0.18 to 0.66
0.57 to 0.89
0.44 to 0.97
I² = 62%, P = .05
0.64 to 0.92
0.36 to 0.71
0.36 to 1.19
0.48 to 0.96
0.54 to 0.99
0.52 to 1.82
0.28 to 0.90
0.48 to 0.99
0.56 to 0.76
0.56 to 0.76
I² = 0%, P = .51
0.56 to 0.75
0.64 to 1.40
0.61 to 1.88
0.72 to 1.36
0.72 to 1.36
I² = 0%, P = .74
0.71 to 1.29
0.69 to 1.16
0.69 to 1.30
0.75 to 1.11
0.75 to 1.11
I² = 0%, P = .79
0.73 to 1.06
0.72 to 3.45
0.59 to 1.67
0.75 to 1.76
0.75 to 1.76
I² = 0%, P = .35
0.72 to 1.25
0.36 to 1.19
0.47 to 1.30
0.50 to 1.07
0.50 to 1.07
I² = 0%, P = .66
0.68 to 1.05
0.2 1 1.8
HR
0.88
0.75
0.70
0.80
0.80
0.78
0.85
0.75
0.61
0.43
0.72
0.68
0.77
0.43
0.63
0.71
0.67
0.92
0.54
0.65
0.62
0.62
0.62
0.85
0.82
0.84
0.84
0.84
0.86
0.92
0.88
0.88
0.86
1.59
1.18
1.28
1.28
1.13
0.82
0.73
0.76
0.76
0.81
Progression-Free Survival
95% CI
0.67 to 1.16
0.58 to 0.99
0.39 to 1.28
0.67 to 0.96
0.67 to 0.96
I² = 0%, P = .65
0.66 to 0.93
0.65 to 1.11
0.45 to 1.25
0.36 to 1.01
0.24 to 0.76
0.59 to 0.89
0.51 to 0.91
I² = 40%, P = .17
0.65 to 0.91
0.31 to 0.61
0.37 to 1.06
0.51 to 1.00
0.50 to 0.90
0.51 to 1.67
0.31 to 0.95
0.46 to 0.92
0.54 to 0.72
0.53 to 0.74
I² = 19%, P = .29
0.54 to 0.71
0.58 to 1.25
0.49 to 1.37
0.62 to 1.14
0.62 to 1.14
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Fig 2. Forest plot for overall survival (on the left) and progression-free survival (on the right), showing results from direct comparisons and network meta-analysis. HR, 1
is in favor of the ﬁrst treatment mentioned in the title (ie, IC-RT for the comparison IC-RT v RT). Only comparisons involving two trials or more are presented here. For
comparisons with only one trial, the hazard ratios used are reported in the Data Supplement. AC, adjuvant chemotherapy; CRT, concomitant chemoradiotherapy; HR,
hazard ratio; IC, induction chemotherapy; RT, radiotherapy;
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subnetworks, centered around the comparison between CRT and
CRT-AC,41 CRT, and IC-CRT42 or CRT, CRT-AC, and IC-CRT.44
All four reports concluded that CRT was as efﬁcacious as more
intensiﬁed treatments, such as CRT-AC or IC-CRT, and should be
the preferred treatment in locally advanced NPC. The differences
between their ﬁndings and ours can be explained by the selection
of trials, the performance of analyses on secondary/limited
networks,41,42,44 the use of published data of unchecked quality,
the absence of data updates or use of intent-to-treat analysis, and
the potential inaccuracy of some data used. Indeed, when the HRs
are not reported in the publications, their estimates on the basis of
other parameters, such as survival curves, are known to be im-
precise.45 These differences might be diluted and less easy to point
out in NMA compared with standard meta-analysis, because the
amount of data analyzed and statistical tests produced can be
overwhelming for readers. We believe that the high quality of data
with updated follow-up, the use of IPD, multiple standardized
secondary end points such as PFS and locoregional/distant control,
and the rigorous methodology are major strengths of our work.
Our work highlights once more that IPD meta-analyses are the
gold standard method and probably even more so in the context of
NMA. The publication of multiple articles on the same meta-
analysis is also typical of the type of research waste46 that is seen
more and more often. It does not add much value but produces
confusion in the scientiﬁc debate. The use of the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses)
extension to network meta-analyses21 and the prospective regis-
tration of meta-analyses in a centralized database47 might help
select the meta-analyses that are trustworthy in the future.
The present work has limitations. First, patients with stage II
disease or WHO grade I histology were included, but they rep-
resent a minority of patients with NPC in both clinical practice and
trials (Data Supplement). The results of the entire network might
not apply to these patients, and their inclusion might also bias its
results. However, because there was no interaction between tumor
stage and treatment effect in the standard meta-analysis,1 it is
unlikely that the exclusion of such patients would lead to anything
but a lower power of the NMA and increased confusion due to
postrandomization exclusion. Besides, no differences were seen
when using adjusted HRs as input data for the NMA. Second,
although treatment ranking is an attractive output of NMAs,
readers should be aware that the computation of ranking prob-
abilities mostly relies on the point estimates (the hazard and odds
ratios here).19 Ranking is also inﬂuenced by the network geom-
etry.48 To evaluate the certainty that a treatment is superior to
another, attention should be paid to the HR estimates along with
their CIs, as well as the consistency of the HR estimates across
different end points and not entirely rely on the treatment ranking.
Moreover, the ranking uncertainty could not be computed. Third,
incomplete and probably heterogeneous data were available on
acute toxicity, along with few reliable data on late toxicity, and
given the old RT techniques used, even if these data had been
recorded correctly, they would have been difﬁcult to interpret in
light of the major technical changes in radiotherapy techniques.
Fourth, because results on distant control are not entirely robust to
sensitivity analyses, they should be considered with caution. Fifth,
although we have performed a thorough search on the basis of
publications and clinical trial databases, a publication bias cannot
Table 3. Summary Table of the Network Meta-Analysis for Acute Toxicity
Treatment Data
Neutropenia
(16 trials, 4,165 patients,
547 events)
Mucositis
(15 trials, 3,989 patients,
1,439 events)
Hearing Loss
(12 trials, 3,156 patients,
71 events)
Weight Loss
(nine trials, 2,140 patients,
230 events)
P value heterogeneity/inconsistency , .001 .48 1.00 .41
P value heterogeneity (within design) , .001 .81 .97 .36
P value inconsistency (between design) .66 .17 1.00 .41
RT
P-score, % 100 70 60 93
IC-RT
OR (95% CI) 2.75 (0.41 to 18.37) 0.79 (0.51 to 1.23) 0.26 (0.09 to 0.77) 1.37 (0.79 to 2.39)
P-score, % 74 91 96 72
IC-CRT
OR (95% CI) 14.57 (2.86 to 74.15) 1.40 (0.89 to 2.21) 0.81 (0.13 to 5.00) 1.94 (1.01 to 3.73)
P-score, % 16 37 64 45
CRT
OR (95% CI) 2.41 (0.84 to 6.90) 1.77 (1.34 to 2.33) 1.13 (0.34 to 3.80) 1.40 (0.68 to 2.91)
P-score, % 76 16 55 70
CRT-AC
OR (95% CI) 10.49 (5.14 to 21.41) 1.94 (1.56 to 2.41) 4.69 (2.54 to 8.66) 5.10 (2.52 to 10.34)
P-score, % 42 6 10 12
RT-AC
OR (95% CI) 18.00 (5.41 to 59.77) 1.07 (0.68 to 1.71) 1.81 (0.57 to 5.78) 5.54 (3.00 to 10.22)
P-score, % 9 62 38 8
IC-RT-AC
OR (95% CI) 11.71 (1.51 to 90.67) 1.00 (0.62 to 1.61) 4.63 (0.09 to 244.79) —
P-score, % 34 70 27 —
NOTE. Results are presented as ORs, 95%CIs, and P-scores for all treatments comparedwith RT alone. A lower OR and a higher P-score indicate a lower risk of toxicity.
ORs were calculated using ﬁxed-effects models for mucositis, hearing loss, and weight loss, and a random-effects model for neutropenia (because of heterogeneity).
Individual trial (comparison) ORs are given in the Data Supplement. The Data Supplement shows the network for each end point and the complete list of trials included.
Abbreviations: AC, adjuvant chemotherapy; CRT, concomitant chemoradiotherapy; IC, induction chemotherapy; OR, odds ratio; RT, radiotherapy.
ascopubs.org/journal/jco © 2016 by American Society of Clinical Oncology 503
Network Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma
Downloaded from ascopubs.org by 147.8.230.101 on November 9, 2017 from 147.008.230.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
be completely ruled out. Finally, although network meta-analyses
are now accepted by multiple public health agencies as a way to
perform systematic evidence synthesis and guidelines have been
published,21,49 readers should keep in mind the limitations as-
sociated with the use of indirect comparisons.
Our interpretation is that giving more CT to patients with
locally advanced NPC, as induction or adjuvant, provided they
receive concomitant CT, achieves a reduction in recurrence rates.
This statement is supported by the fact that HR and ranking almost
always favor CRT-AC or IC-CRT. The choice of the most suited
regimen for a given patient must include a consideration of the
risk–beneﬁt ratio. The data on IC before CRT remain conﬂicting.
Indeed, a recent randomized trial evaluating induction gemcita-
bine, carboplatin, and paclitaxel followed by CRT versus upfront
CRT was negative,50 whereas a small randomized trial evaluating
induction docetaxel, cisplatin, and ﬂuorouracil before CRT, presented
in 2015, was positive for OS.51 Additional trials on IC should be
reported in the near future and might help clarify this issue
(NCT01245959, NCT01536223, NCT01872962, and NCT02512315).
Ongoing research is warranted in the ﬁelds of systemic treatment and
predictive biomarkers to allow the selection of patients for whom the
addition of AC or IC to CRT would be needed, such as is being
investigated by NRG Oncology using Epstein-Barr virus quantitative
circulating DNA levels (NCT02135042).
Until then, clinical judgment, evaluation of the risk of local
and distant relapse, and discussion with the patient about the
potential risks and beneﬁts of the different treatment regimens
should guide clinical practice. The data presented here should be of
major help because they represent the most up to date and least
biased analysis of the medical literature. Additional data will help
us personalize treatments to each patient’s needs.
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